Platinum-based drugs for cancer therapy and anti-tumor strategies
Citations Over TimeTop 1% of 2022 papers
Abstract
Platinum-based drugs cisplatin, carboplatin, and oxaliplatin are widely used for chemotherapeutic eradication of cancer. However, the side effects of platinum drugs, such as lack of selectivity, high systemic toxicity, and drug resistance, seriously limit their clinical application. With advancements in nanotechnology and chemical synthesis, Pt-based anti-cancer drugs have made great progress in cancer therapy in recent years. Many strategies relied on the anti-cancer mechanism similar to cisplatin and achieved some success by modifying existing platinum drugs. Pt-based nanodrugs, such as platinum nanoclusters, have novel anti-cancer mechanisms and great potential in tumor-targeted therapy and have shown promising results in clinical application. In this review, we systematically explored the development of first-line platinum chemotherapy drugs in the clinic and their anti-cancer mechanisms. We also summarize the progress of Pt-based anti-cancer drug application in cancer therapy, emphasizing their modification to enhance the anti-tumor effect. Finally, we address challenges faced by platinum chemotherapy drugs, especially Pt nanocluster-based nanodrugs, in cancer treatment. The new platinum drugs and their targeted modifications undoubtedly provide a promising prospect for improving the current anti-cancer treatments.
Related Papers
- Oxaliplatin: mechanism of action and antineoplastic activity.(1998)
- → Mechanisms of reaction ofL-methionine with carboplatin and oxaliplatin in different media: a comparison with cisplatin(1999)56 cited
- → Ototoxicity and Platinum Uptake Following Cyclic Administration of Platinum-Based Chemotherapeutic Agents(2020)45 cited
- → Cisplatin, oxaliplatin, and carboplatin unequally inhibit in vitro mRNA translation(2013)37 cited
- → Oxaliplatin is active in vitro against human melanoma cell lines: comparison with cisplatin and carboplatin(2000)23 cited